CAR-T for Pediatric B-ALL: Expert Tips

What has been the most exciting thing that you've seen so far at this congress?

Maybe the fourth generation CAR.

If I could invest today in a new model of CAR, this would be my, my guess, which would be at the same time double targeting and promoting the CAR by cytokines.

This is probably a way to go.

And the next future, let's say that the difficult Part of the job is that you take out the cell of the body, and you do a lot of things in vitro, very expensive way.

You need special factories, et cetera, and then you re-infuse the cell.

The idea would say, if the body itself would be the cell factory, so the people are trying, and there have been few companies acquired for this by the industry, few biotechs, to do in vivo CAR contrary to ex vivo CAR.

So then the idea would be to infuse the construct directly, and you need a vector for this, either a viral construct or a so-called lipid nanoparticle.

For example, the COVID vaccine was infused in a lipid nanoparticle.

So the question would be, let's infuse this thing directly in the body, but we will have predicted the way that this construct goes right into the immune cells I want it to go to.

And second, that there is an expansion in the body, and third, that it kills the cell I want to kill.

This seems science fiction, but there have been already some success, early success in myeloma in adults, and, uh, this is really an extremely fascinating field, as you can imagine.

And probably the first data of the first trials will appear during year twenty twenty-six or twenty twenty-seven.

And there is, let's say, a hype in the field about in vivo CAR.

Mm-hmm.

Because if in vivo CAR works, a lot of things ex vivo will disappear, not all, but a lot of them.

Hmm.

Very exciting.

Very fascinating.